Cite
HARVARD Citation
Visvanathan, S. et al. (n.d.). Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study. Journal of Crohn's and colitis. pp. 1170-1179. [Online].